Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1750 of 2026 entries
View as:

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05835986 Org: User:
Start: 12/18/23 End: 11/30/27 Due: 11/30/28

A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01388959 Org: User:
Start: 11/30/98 End: 04/30/04 Due: 04/30/05

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00413101 Org: User:
Start: - End: 03/31/08 Due: 03/31/09

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01491737 Org: User:
Start: 02/17/12 End: 11/14/19 Due: 11/14/20

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT03669640 Org: User:
Start: 12/04/18 End: 03/12/23 Due: 03/12/24

An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

Phase: N/A Priority: Normal
NCT ID: NCT01480674 Org: User:
Start: 03/28/11 End: 11/16/12 Due: 11/16/13

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05645692 Org: User:
Start: 04/13/23 End: 12/30/26 Due: 12/30/27

A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01654211 Org: User:
Start: 07/31/12 End: 11/30/12 Due: 11/30/13

Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate

Phase: N/A Priority: Normal
NCT ID: NCT00569452 Org: User:
Start: 01/31/06 End: 05/31/06 Due: 05/31/07

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03285763 Org: User:
Start: 10/25/17 End: 04/07/22 Due: 04/07/23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00950300 Org: User:
Start: 10/16/09 End: 01/24/17 Due: 01/24/18

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01253564 Org: User:
Start: 11/22/10 End: 03/14/12 Due: 03/14/13

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01495104 Org: User:
Start: 10/31/11 End: 01/31/12 Due: 01/31/13

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01164891 Org: User:
Start: 07/31/10 End: 12/31/12 Due: 12/31/13

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00048022 Org: User:
Start: 10/25/02 End: 02/02/04 Due: 02/02/05

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05129280 Org: User:
Start: 01/25/22 End: 07/12/23 Due: 07/12/24

Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02708732 Org: User:
Start: 05/31/16 End: 10/31/16 Due: 10/31/17

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT04434092 Org: User:
Start: 10/08/20 End: 09/30/27 Due: 09/30/28

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT02484690 Org: User:
Start: 08/11/15 End: 09/26/17 Due: 09/26/18

PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01659970 Org: User:
Start: 06/30/12 End: 04/30/14 Due: 04/30/15

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03800836 Org: User:
Start: 02/13/18 End: 03/16/22 Due: 03/16/23

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Phase: N/A Priority: Normal
NCT ID: NCT00988325 Org: User:
Start: 01/31/11 End: 04/30/12 Due: 04/30/13

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03596632 Org: User:
Start: 07/27/18 End: 08/23/18 Due: 08/23/19

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00121784 Org: User:
Start: 10/31/05 End: 08/31/06 Due: 08/31/07

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02908672 Org: User:
Start: 01/13/17 End: 07/01/24 Due: 07/01/25